The closing price of ARS Pharmaceuticals Inc. (NASDAQ: SPRY) was $7.44 for the day, up 2.48% from the previous closing price of $7.26. In other words, the price has increased by $+0.18 from its previous closing price. On the day, 855696 shares were traded.
In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.
Click here for full details and to join for free
Ratios:
Our analysis of SPRY’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 25.40 and its Current Ratio is at 25.40. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Wedbush on January 31, 2023, initiated with a Outperform rating and assigned the stock a target price of $10.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Sep 01 when Shawver Laura sold 100,000 shares for $7.71 per share. The transaction valued at 770,520 led to the insider holds 210,346 shares of the business.
RA CAPITAL MANAGEMENT, L.P. bought 3,750,000 shares of SPRY for $23,250,000 on Aug 29. The Director now owns 5,856,774 shares after completing the transaction at $6.20 per share. On Aug 29, another insider, ORBIMED ADVISORS LLC, who serves as the Director of the company, bought 500,000 shares for $6.20 each. As a result, the insider paid 3,100,000 and bolstered with 8,019,187 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SPRY now has a Market Capitalization of 711.03M and an Enterprise Value of 459.20M. For the stock, the TTM Price-to-Sale (P/S) ratio is 548.44 while its Price-to-Book (P/B) ratio in mrq is 2.84. Its current Enterprise Value per Revenue stands at 2.10k whereas that against EBITDA is -7.52.
Stock Price History:
Over the past 52 weeks, SPRY has reached a high of $9.65, while it has fallen to a 52-week low of $3.99. The 50-Day Moving Average of the stock is 7.04, while the 200-Day Moving Average is calculated to be 7.18.
Shares Statistics:
SPRY traded an average of 541.19K shares per day over the past three months and 719.93k shares per day over the past ten days. A total of 94.91M shares are outstanding, with a floating share count of 66.93M. Insiders hold about 10.50% of the company’s shares, while institutions hold 34.30% stake in the company. Shares short for SPRY as of Aug 30, 2023 were 5.37M with a Short Ratio of 5.37M, compared to 6.07M on Jul 30, 2023. Therefore, it implies a Short% of Shares Outstanding of 5.62% and a Short% of Float of 9.07%.
Earnings Estimates
The firm’s stock currently is rated by 3 analysts. On average, analysts expect EPS of -$0.2 for the current quarter, with a high estimate of -$0.16 and a low estimate of -$0.26, while EPS last year was -$0.5. The consensus estimate for the next quarter is -$0.27, with high estimates of -$0.16 and low estimates of -$0.38.
Analysts are recommending an EPS of between -$0.69 and -$0.98 for the fiscal current year, implying an average EPS of -$0.81. EPS for the following year is -$0.97, with 3 analysts recommending between -$0.75 and -$1.31.
Revenue Estimates
A total of 3 analysts have provided revenue estimates for SPRY’s current fiscal year. The highest revenue estimate was $4.44M, while the lowest revenue estimate was $800k, resulting in an average revenue estimate of $2.59M. In the same quarter a year ago, actual revenue was $1.32M, up 96.80% from the average estimate. Based on 3 analysts’ estimates, the company’s revenue will be $42.7M in the next fiscal year. The high estimate is $48.9M and the low estimate is $34.65M. The average revenue growth estimate for next year is up 1,548.60% from the average revenue estimate for this year.